Guidance Document for Industry - Review of Drug Brand Names

Guidance Document for Industry - Review of Drug Brand Names To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors. 2021-07-07 Health Canada open-ouvert@tbs-sct.gc.ca Health and SafetyGuidance document for industryreview of drug brand namesmarket authorizationa proposed name to be misleadingconfused with another productauthorized for usepreventing medication errors Guidance Document for Industry - Review of Drug Brand NamesHTML https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-industry-review-drug-brand-names.html#a1 Guidance Document for Industry - Review of Drug Brand NamesHTML https://www.canada.ca/fr/sante-canada/services/medicaments-produits-sante/rapports-publications/medeffet-canada/ligne-directrice-intention-industrie-examen-marques-nominatives-medicament.html#a

To provide market authorization holders direction on the process to be followed and information to be submitted to Health Canada regarding the potential for a proposed name to be misleading or confused with another product authorized for use in Canada with the aim of preventing medication errors.

Data and Resources

Similar records